John Risvanis

1.4k total citations
27 papers, 1.2k citations indexed

About

John Risvanis is a scholar working on Social Psychology, Pulmonary and Respiratory Medicine and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, John Risvanis has authored 27 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Social Psychology, 19 papers in Pulmonary and Respiratory Medicine and 7 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in John Risvanis's work include Neuroendocrine regulation and behavior (19 papers), Electrolyte and hormonal disorders (18 papers) and Hormonal Regulation and Hypertension (6 papers). John Risvanis is often cited by papers focused on Neuroendocrine regulation and behavior (19 papers), Electrolyte and hormonal disorders (18 papers) and Hormonal Regulation and Hypertension (6 papers). John Risvanis collaborates with scholars based in Australia. John Risvanis's co-authors include Louise M. Burrell, Colin I. Johnston, Christos Tikellis, Mark E. Cooper, Paddy A. Phillips, Josephine M. Forbes, Wendy C. Burns, Sharon Grant, Rachael Dean and Rebecca A. Lew and has published in prestigious journals such as Kidney International, Hypertension and European Heart Journal.

In The Last Decade

John Risvanis

27 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John Risvanis Australia 16 552 391 284 271 259 27 1.2k
Mohapradeep Mohan United Kingdom 10 311 0.6× 368 0.9× 77 0.3× 392 1.4× 30 0.1× 42 1.0k
Xie Wu United States 11 284 0.5× 310 0.8× 76 0.3× 124 0.5× 18 0.1× 18 849
Sho Sasaki Japan 15 383 0.7× 113 0.3× 58 0.2× 159 0.6× 64 0.2× 67 932
F. Javier Salazar Spain 23 607 1.1× 242 0.6× 155 0.5× 198 0.7× 29 0.1× 86 1.7k
Martin Bald Germany 16 192 0.3× 222 0.6× 105 0.4× 231 0.9× 20 0.1× 49 815
Yoram Shenker United States 17 653 1.2× 339 0.9× 222 0.8× 127 0.5× 25 0.1× 40 1.2k
Dominik Steubl Germany 21 219 0.4× 278 0.7× 309 1.1× 231 0.9× 17 0.1× 63 1.2k
Roberto Della Bruna Switzerland 15 480 0.9× 210 0.5× 82 0.3× 337 1.2× 17 0.1× 30 734
TOHRU YAMAJI Japan 21 400 0.7× 514 1.3× 276 1.0× 179 0.7× 46 0.2× 52 1.2k
Hiroshi Sekino Japan 19 808 1.5× 187 0.5× 114 0.4× 107 0.4× 33 0.1× 74 1.3k

Countries citing papers authored by John Risvanis

Since Specialization
Citations

This map shows the geographic impact of John Risvanis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Risvanis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Risvanis more than expected).

Fields of papers citing papers by John Risvanis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Risvanis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Risvanis. The network helps show where John Risvanis may publish in the future.

Co-authorship network of co-authors of John Risvanis

This figure shows the co-authorship network connecting the top 25 collaborators of John Risvanis. A scholar is included among the top collaborators of John Risvanis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Risvanis. John Risvanis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Burrell, Louise M., John Risvanis, Rachael Dean, et al.. (2012). Age-dependent regulation of renal vasopressin V1A and V2 receptors in rats with genetic hypertension: implications for the treatment of hypertension. Journal of the American Society of Hypertension. 7(1). 3–13. 13 indexed citations
2.
Burrell, Louise M., John Risvanis, Eiji Kubota, et al.. (2005). Myocardial infarction increases ACE2 expression in rat and humans. European Heart Journal. 26(4). 369–375. 345 indexed citations
3.
Koukoulas, Irene, John Risvanis, R. N. Douglas-Denton, et al.. (2003). Vasopressin Receptor Expression in the Placenta. Biology of Reproduction. 69(2). 679–686. 14 indexed citations
4.
Tikellis, Christos, Colin I. Johnston, Josephine M. Forbes, et al.. (2003). Characterization of Renal Angiotensin-Converting Enzyme 2 in Diabetic Nephropathy. Hypertension. 41(3). 392–397. 294 indexed citations
5.
Burrell, Louise M., et al.. (2000). Vasopressin receptor antagonism — a therapeutic option in heart failure and hypertension. Experimental Physiology. 85(s1). 259S–265S. 32 indexed citations
6.
Risvanis, John, Mareo Naitoh, Colin I. Johnston, & Louise M. Burrell. (1999). In vivo and in vitro characterisation of a nonpeptide vasopressin V1A and V2 receptor antagonist (YM087) in the rat. European Journal of Pharmacology. 381(1). 23–30. 29 indexed citations
7.
Naitoh, Mareo, John Power, Paddy A. Phillips, et al.. (1998). Effects of Chronic AVP V2R Blockade in Congestive Heart Failure in Sheep. Advances in experimental medicine and biology. 449. 445–446. 5 indexed citations
8.
Johnston, Colin I., et al.. (1998). Mechanism of progression of renal disease: current hemodynamic concepts.. PubMed. 16(4). S3–7. 19 indexed citations
9.
Burrell, Louise M., et al.. (1997). Chronic Vasopressin Antagonism in Two-Kidney, One-Clip Renovascular Hypertension. Clinical and Experimental Hypertension. 19(5-6). 981–991. 9 indexed citations
10.
Burrell, Louise M., et al.. (1997). Inhibition of Neutral Endopeptidase, the Degradative Enzyme for Natriuretic Peptides, in rat Kidney after Oral SCH 42495. Clinical Science. 93(1). 43–50. 17 indexed citations
11.
Phillips, Paddy A., et al.. (1995). Differential Effects of a Novel Non-Peptide Endothelin Receptor Antagonist (Bosentan) in Rat Liver and Vasculature. Clinical Science. 89(6). 575–579. 4 indexed citations
12.
Grant, Sharon, et al.. (1994). Epidermal growth factor antagonizes vasopressin in vivo and in vitro. Kidney International. 45(4). 1028–1036. 15 indexed citations
13.
Gao, Xin, Paddy A. Phillips, Brian J. Oldfield, et al.. (1994). Androgen manipulation and vasopressin binding in the rat brain and peripheral organs. European Journal of Endocrinology. 130(3). 291–296. 7 indexed citations
14.
Burrell, Louise M., et al.. (1994). Vasopressin and a Nonpeptide Antidiuretic Hormone Receptor Antagonist (OPC-31260). Blood Pressure. 3(1-2). 137–141. 11 indexed citations
15.
Burrell, Louise M., et al.. (1994). EFFECTS OF ANTI‐EMETICS ON WATER EXCRETION IN HUMANS. Clinical and Experimental Pharmacology and Physiology. 21(1). 59–62. 2 indexed citations
16.
Burrell, Louise M., et al.. (1994). Blood pressure-lowering effect of an orally active vasopressin V1 receptor antagonist in mineralocorticoid hypertension in the rat.. Hypertension. 23(6_pt_1). 737–743. 52 indexed citations
17.
Burrell, Louise M., et al.. (1993). Characterization of a novel non-peptide vasopressin V1 receptor antagonist (OPC-21268) in the rat. Journal of Endocrinology. 138(2). 259–266. 17 indexed citations
18.
Burrell, Louise M., et al.. (1993). EFFECTS OF AN ORALLY ACTIVE VASOPRESSIN V1 RECEPTOR ANTAGONIST. Clinical and Experimental Pharmacology and Physiology. 20(5). 388–391. 6 indexed citations
19.
Phillips, Paddy A., et al.. (1993). Effects of drinking on thirst and vasopressin in dehydrated elderly men. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 264(5). R877–R881. 55 indexed citations
20.
Trinder, Deborah, et al.. (1991). [3H]desGly-NH29-d(CH2)5[D-Ileu2,Ileu4]AVP: An AVP V2 receptor antagonist radioligand. Peptides. 12(6). 1195–1200. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mohapradeep Mohan Breakdown of academic impact, for papers by Xie Wu Breakdown of academic impact, for papers by Sho Sasaki Breakdown of academic impact, for papers by F. Javier Salazar Breakdown of academic impact, for papers by Martin Bald Breakdown of academic impact, for papers by Yoram Shenker Breakdown of academic impact, for papers by Dominik Steubl Breakdown of academic impact, for papers by Roberto Della Bruna Breakdown of academic impact, for papers by TOHRU YAMAJI Breakdown of academic impact, for papers by Hiroshi Sekino
Rankless by CCL
2026